Skip to main content

Table 4 Patients with EF or GLS changes and their peak hs-TnT

From: Detection of subclinical cardiotoxicity in sarcoma patients receiving continuous doxorubicin infusion or pre-treatment with dexrazoxane before bolus doxorubicin

Prevention strategy

Sex

Age

Ejection Fraction

Global Strain

Peak hs-TnT

Pre

C3

End

Pre

C3

End

Dexrazoxane

M

65

60.5

55

55.2

NA

NA

NA

39.37

Dexrazoxane

F

38

57.1

54.7

50.2

−20.8

−20.4

−16.3

11.01

Dexrazoxane

F

43

70.2

65.3

61.1

−25.9

−21.9

−21.9

10.29

Dexrazoxane

F

49

57.7

51.5

51.6

−21.1

−17.5

−16

4.6

Continuous

M

71

61.3

55.4

55.6

−22.9

−19.1

−15.8

44.07

Continuous

F

24

60.7

53.9

55.3

−20.4

−19.6

−18.1

10.77

Continuous

M

40

57.2

49.9

52

−19.3

−18.1

− 19.3

6.13

Cross Over

F

42

62.3

60.2

55.8

−21

−22.4

−20.1

3.76

  1. NA not available, due to technical limitation